





Please <u>initial</u>

box. <u>Do</u> not tick

CONSENT FORM

Plasma biomarkers in stratifying patients referred via the lower gastro-intestinal (LGI) suspected cancer two-week wait (2WW) pathway MOTION study

Participant ID:

Please read the statements below. Put <u>initials</u> of your name in the boxes if you agree, put an X in any box where you do not agree and sign the form. Use BLACK pen only		
1. I confirm that I have read and understand the Patient Information Sheet dated [DATE] (version		
[VERSION NUMBER]) for MOTION study. I have had the opportunity to consider the information, ask		
questions and have had these answered satisfactorily.		
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without		
giving any reason and without my care or legal rights being affected.		
3. I agree that confidential study data collected prior to my withdrawal from the MOTION study can be		
used in the study reports. I understand that if I lose capacity to consent during the study I will be		
withdrawn and the agreed data already collected can be used.		
4. I understand that relevant sections of my medical notes and data collected during the MOTION study		
may be looked at by individuals from the Queen Mary, University of London (QMUL) or Barts Health		
NHS Trust (BHT). I give permission for these individuals to have access to my records.		
5. I agree for my contact details and identifiable personal data to remain within the study site (QMUL or		
BHT). I understand that coded personal data, including data from medical records and study-specific		
data, may be shared with collaborators within the EU for the purposes of research and data analysis.		
6. I agree to my GP or/ and referring doctors being informed of my participation in the MOTION study.		
7. I understand that the study data collected will be used for medical research only. I will be given a		
Unique Identification Number (UIN/ Patient ID) in order to ensure that my data is confidential and will not		
directly identify me.		
8. I agree my confidential study data can be used in the analysis and reporting of the study findings.		
9. I understand that participants will be asked to give a 20 millilitres of blood sample, to be taken in clinic		
or in endoscopy or in the radiology department. I consent to having my blood drawn.		
10. I understand that a laboratory will analyse my blood sample and the MOTION study team will record		
this information.		
11. I understand that a part of my blood sample will be transported to our collaborators in France.		
A portion of the blood sample collected for this study will be sent to Progastrin Manufacturing, Biodena		

Care, located at Cap Sigma-Zac Euromedicine II, 1682 Rue de la Vasière, 34790 Grabels, France, for

12. I understand that this MOTION study also involves the analysis of my DNA and RNA from plasma

13. I understand that the storage of my samples will be pseudonymised (labelled with an ID number

instead of personally identifying information) and outcomes of the analysis are unlikely

Copies: 1 for patient; 1 for study team, 1 for medical notes IRAS number: 321809 Patient Informed Consent Form_v1.5_7th April 25

the purpose of biomarker analysis.

and I agree for genetic analysis to be done.







to have any implications for me personally.			
14. I understand that my contact details will be kept in order for the study team to communicate with me			
about the study and for QMUL to retain study-related information for 5 years after the study ends, after			
which point all study materials will be destroyed.			
15. I understand that relevant sections of my medical notes and data collected during			
the study may be looked at by individuals from QMUL or BHT, from regulatory authorities or			
from the NHS Trust, where it is relevant to my taking part in this research. I give permission for			
these individuals to have access to my records.			
16. I agree to take part in the study.			
17. OPTIONAL			
I agree to be contacted by the study team to complete a survey at the end of the two-week wait			
pathway using my contact details.			
18. OPTIONAL			
I prefer to be informed and receive information about this questionnaire through the following			
methods.	□ phone intervie	w 🗆 SMS	
19. OPTIONAL			
I understand that the information collected about me will be used to support other research in the			
future and may be shared anonymously with other researchers.			
20. OPTIONAL			
Following the present study, any residual (left-over) plasma may be stored and used by the research			
team at QMUL, for future research studies. Any future studies will have Ethics Committee permission.			
21. OPTIONAL			
I agree to be contacted about future related stud	lies.		
Print Name of Participant:	Date:	Participant's Signature:	
Print Name of person taking consent:	Date:	Signature of person taking cor	nsent: